Company says that its D-BHB energy-support ingredient, which increases levels of blood ketones, is the first to be FDA GRAS-notified
The company says D-BHB can increase levels of blood ketones without requiring users to consume excess calories and fat associated with a typical low-carb diet.
Photo © iStockphoto.com
Osaka Gas Chemicals Company, Ltd., (Osaka, Japan) says that its D-β-hydroxybutyric acid (D-BHB) ingredient, brand name Oketoa, is the first D-BHB ingredient to receive a “no objection” letter from the U.S. FDA following submission of a Generally Recognized as Safe (GRAS) notification. The ingredient’s GRAS status means it can be sold in food and drinks in the U.S. The company is now launching the ingredient in the U.S. market.
According to the company, “One of the many functional benefits of D-BHB is that it can increase levels of blood ketones without consumption of the excess calories and fat associated with a typical low-carb diet.”
The company adds that Oketoa is the only D-BHB ingredient produced from sugar using a natural, patented, non-GMO precision-fermentation process. The company’s fermentation process uses nonrecombinant bacteria.
“Our high-quality, naturally and precision-fermented D-BHB ingredient is perfectly suited as a functional ingredient in food and beverage applications for a multitude of energy-support applications, including high-performance nutrition,” said Mariko Kato, PhD, deputy research director of Osaka Gas, in a press release.
Magnesium L-threonate, Magtein, earns novel food authorization in the European Union
December 19th 2024According to the announcement, the authorization is also exclusive to AIDP and its partner company and licensee, ThreoTech, meaning that they are the only parties that can market magnesium L-threonate in the EU for a period of five years.
Kelker Pharma to launch nutritional support system for GLP-1 medication users that features TriBsyn
December 11th 2024B&D Nutritional Ingredients Inc., an exclusive distribution partner of CarnoSyn Brands and Natural Alternatives International Inc., announced that its customer, Kelker Pharma, will be launching the “first science-backed nutritional support system” for GLP-1 medication users, called Nutrilinq Genesis.
